Karachalios G N, Donas G
Int J Tissue React. 1982;4(4):297-9.
Sulindac is a new non-steroidal drug which is currently available for the treatment of rheumatoid arthritis, osteo-arthritis and ankylosing spondylitis throughout the world. We have recently assessed on open trial of this drug in acute gout arthritis of 26 patients (16 men and ten women). Their ages ranged from 40 to 62 years. All the patients entered in the study provided the fulfilled rigid criteria. Patients received 400 mg in two separate doses in the morning and evening for seven days. There was a dramatic improvement in the joint pain in 15 patients in the first 24 hours and only one after 48 hours, swelling and tenderness improved after four days. No significant side-effects and no significant changes in any of the laboratory tests were observed. Our conclusion is that sulindac is a very useful drug in the treatment of acute gout arthritis.
舒林酸是一种新型非甾体类药物，目前在全球可用于治疗类风湿性关节炎、骨关节炎和强直性脊柱炎。我们最近对26例急性痛风性关节炎患者（16名男性和10名女性）进行了该药的开放试验。他们的年龄在40至62岁之间。所有纳入研究的患者均符合严格标准。患者早晚分两次各服用400毫克，共服用七天。15例患者在最初24小时内关节疼痛有显著改善，48小时后仅有1例改善，肿胀和压痛在四天后有所改善。未观察到明显的副作用，实验室检查也未出现明显变化。我们的结论是，舒林酸在治疗急性痛风性关节炎方面是一种非常有用的药物。
